Real-World Studies
Routine CBC Features Linked to Higher Diagnostic Yield in JAK2 V617F Testing
Nagendra et alAmerican journal of clinical pathology

In a retrospective analysis of 2,979 qualitative JAK2 V617F test orders evaluated between October 2025 and February 2026 at a large reference laboratory, researchers assessed diagnostic yield and complete blood count (CBC) associations to inform laboratory stewardship. Overall, 136 of 2,979 tests (4.6%) yielded positive results.
The presence of at least one prespecified hematologic feature was associated with an increased diagnostic yield compared with the absence of these features (6.2% vs 2.1%; odds ratio, 3.07; 95% CI, 1.98–4.77; P < .001). Among specific parameters, basophilia and thrombocytosis had the highest positivity rates at 41.1% and 24.5%, respectively. Differential count analysis also identified modest associations between monocyte and eosinophil counts and test positivity.
Tests performed in the absence of any prespecified hematologic feature comprised 39.9% of all orders and exhibited lower efficiency, requiring 47.5 tests to detect one positive case. Financial modeling based on the 2026 Medicare Clinical Laboratory Fee Schedule rate of $91.66 per test estimated an expenditure of $108,900 over 5 months, or $261,000 annually, for tests ordered without these hematologic indicators. Because clinical indications were not available in the dataset, the authors noted that testing performed without these features cannot be categorized as inappropriate, but routine CBC criteria could provide a framework for targeted clinical decision support.
Key Takeaways
- In an analysis of 2,979 qualitative JAK2 V617F test orders, testing with at least one prespecified complete blood count feature showed a higher diagnostic yield than testing without (6.2% vs 2.1%; odds ratio, 3.07; 95% CI, 1.98–4.77; P < .001), with basophilia (41.1%) and thrombocytosis (24.5%) having the highest positivity rates.
- Testing without any prespecified hematologic feature represented 39.9% of total orders, required 47.5 tests per positive result, and corresponded to a modeled financial impact of $108,900 over 5 months ($261,000 annually) at 2026 Medicare fee schedule rates.
Read the original sourceAmerican journal of clinical pathology
